Target
cMET
5 abstracts
Abstract
MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh, Medical College of Wisconsin, Next Oncology Virginia and Virginia Cancer Specialists, Medical University of South Carolina Hollings Cancer Center,
Abstract
Risk factors for venous thromboembolism (VTE) among patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.Org: Institut Curie, Saint Cloud, France, Virginia Cancer Specialists, Columbia University Medical Center, Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Providence Cancer Institute,
Abstract
Phase 1 multicenter dose escalation and dose expansion study of antibody-drug conjugate (ADC) MYTX-011 in subjects with non-small cell lung cancer.Org: NEXT Oncology - Virginia Cancer Specialists, The Sarah Cannon Research Institute, Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, UPMC Hillman Cancer Center, Medical College of Wisconsin,
Abstract
Analysis of different color unmixing methods for cMET-PDL1-EGFR multiplex assay.Org: Rochester Regional Health System, Santa Clara, CanSino Biologics, Tucson, AZ, Azidus Brasil,
Abstract
Preliminary dose escalation results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET trispecific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).Org: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, Genesis Care North Shore, North Shore Health Hub, St Leonards, NSW, Australia,